Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in...
Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk New ESC Congress 2026 data, published simultaneously in EJNMMI, show that AI-quantified plaque burden was independently associated with cardiovascular events at 3,...
Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease The Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica’s proprietary multi-ancestry PRS technology, gives physicians a new option to identify and evaluate...
Bluesight Launches Prism Assistant in PrivacyPro, Bringing AI-Powered Investigations to Patient Privacy TeamsBy Chancy Whitby Prism Assistant helps privacy teams accelerate investigations, reporting, and analysis – while keeping sensitive patient access data secure....
Incyte To Acquire Vega Therapeutics, A Wholly Owned Subsidiary Of Star Therapeutics, Expanding Its Hematology Portfolio Into Bleeding Disorders – Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3...
Recent Comments